Загрузка...
Inhibiting the hypoxia response for cancer therapy – the new kid on the block
The HIF-1α inhibitor KC7F2 described in this issue of Clinical Cancer Research is the newest addition to an emerging class of antitumor agents targeting the hypoxia response. Here we discuss the proposed mechanism of action of KC7F2 and its potential strengths and limitations in comparison with othe...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2009
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2760048/ https://ncbi.nlm.nih.gov/pubmed/19789327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1650 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|